Matches in UGent Biblio for { <https://biblio.ugent.be/publication/5809147#aggregation> ?p ?o. }
Showing items 1 to 48 of
48
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B928621.
- aggregation creator B928622.
- aggregation creator B928623.
- aggregation creator B928624.
- aggregation creator B928625.
- aggregation creator B928626.
- aggregation creator B928627.
- aggregation creator B928628.
- aggregation creator B928629.
- aggregation creator B928630.
- aggregation creator B928631.
- aggregation creator B928632.
- aggregation creator B928633.
- aggregation creator B928634.
- aggregation creator B928635.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 5809147.bibtex.
- aggregation hasFormat 5809147.csv.
- aggregation hasFormat 5809147.dc.
- aggregation hasFormat 5809147.didl.
- aggregation hasFormat 5809147.doc.
- aggregation hasFormat 5809147.json.
- aggregation hasFormat 5809147.mets.
- aggregation hasFormat 5809147.mods.
- aggregation hasFormat 5809147.rdf.
- aggregation hasFormat 5809147.ris.
- aggregation hasFormat 5809147.txt.
- aggregation hasFormat 5809147.xls.
- aggregation hasFormat 5809147.yaml.
- aggregation isPartOf urn:issn:1554-8929.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens".
- aggregation abstract "The emergence of multiple-drug-resistant (MDR) bacterial pathogens in hospitals (nosocomial infections) presents a global threat of growing importance, especially for Gram-negative bacteria with extended spectrum β-lactamase (ESBL) or the novel New Delhi metallo-β-lactamase 1 (NDM-1) resistance. Starting from the antibacterial peptide apidaecin 1b, we have optimized the sequence to treat systemic infections with the most threatening human pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The lead compound Api88 enters bacteria without lytic effects at the membrane and inhibits chaperone DnaK at the substrate binding domain with a KD of 5 μmol/L. The Api88-DnaK crystal structure revealed that Api88 binds with a seven residue long sequence (PVYIPRP), in two different modes. Mice did not show any sign of toxicity when Api88 was injected four times intraperitoneally at a dose of 40 mg/kg body weight (BW) within 24 h, whereas three injections of 1.25 mg/kg BW and 5 mg/kg BW were sufficient to rescue all animals in lethal sepsis models using pathogenic E. coli strains ATCC 25922 and Neumann, respectively. Radioactive labeling showed that Api88 enters all organs investigated including the brain and is cleared through both the liver and kidneys at similar rates. In conclusion, Api88 is a novel, highly promising, 18-residue peptide lead compound with favorable in vitro and in vivo properties including a promising safety margin.".
- aggregation authorList BK1312582.
- aggregation endPage "1291".
- aggregation issue "7".
- aggregation startPage "1281".
- aggregation volume "7".
- aggregation aggregates 5809149.
- aggregation isDescribedBy 5809147.
- aggregation similarTo cb300063v.
- aggregation similarTo LU-5809147.